ChemotherapyFDA-approvedFirst-line

Alimta (Pemetrexed)

Generic name: pemetrexed

How it works

Interferes with the growth and spread of cancer cells by blocking the production of DNA and RNA.

Cancer types

Lung CancerAll patients

Efficacy

In clinical trials, pemetrexed improved overall survival in patients with non-small cell lung cancer, with a median overall survival of approximately 10 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

Evidence from research

StudyCancer typeStageEfficacy
Rare Skin Reaction Linked to Lung Cancer TreatmentLung CancerobservationalSource →
New Treatment Combination Tested for Lung Cancer Patients with Brain MetastasesLung Cancerphase-1Source →
Testing Sacituzumab Tirumotecan in Advanced Lung CancerLung Cancerphase-3Source →
Testing Methoxyamine with Cisplatin and Pemetrexed in Advanced Cancer PatientsLung Cancerphase-1Source →
Traditional Chinese Medicine May Help Reduce Chemotherapy Side Effects in Lung Cancer PatientsLung Cancerphase-3The incidence of neurotoxicity was 29.1% in the treatment group, significantly lower than 51.8% in the control group.Source →
Taxane Chemotherapy May Be More Effective Than Pemetrexed in Lung CancerLung CancerobservationalTaxanes showed numerically longer progression-free survival (PFS; median 8.8 vs 7.9 months) and overall survival (OS; 18.8 vs 15.9 months) versus pemetrexed.Source →
Pemetrexed Side Effects Study Identifies New Safety SignalsLung CancerobservationalSource →
New Treatment Combination Shows Promise for Lung Cancer PatientLung CancerobservationalThe treatment successfully prolonged the patient's survival by 3 months.Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.